Coccidioidomycosis in patients who have undergone transplantation

Janis E. Blair

Research output: Chapter in Book/Report/Conference proceedingConference contribution

42 Citations (Scopus)

Abstract

In the early years of transplantation in Arizona, coccidioidomycosis occurred in 7% to 9% of recipients, with a mortality rate as high as 72% in some cases. In current transplant programs, however, evolution of immunosuppression and institution of targeted prophylaxis have resulted in coccidioidal infection rates ranging from 1% to 2%. The clinical characteristics of this infection among transplant recipients range from asymptomatic to fulminant and fatal. Dissemination is common, and mortality is high (28%). Because serologic response is often absent or slow, diagnosis can be challenging and often requires invasive diagnostic procedures. Pharmacologic treatment follows the guidelines of the Infectious Diseases Society of America, but control of infection may also dictate a decrease in immunosuppressant treatment. After infection is controlled, secondary azole prophylaxis is recommended to prevent relapse. Patients with a history of coccidioidomycosis may undergo successful transplantation when disease is inactive and azole prophylaxis is instituted. The incidence of donor-derived coccidioidomycosis is not known. The risk of coccidioidal infection among transplant recipients visiting in or relocating to an endemic area is low, and routine prophylaxis for this group is not recommended.

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
Pages365-376
Number of pages12
Volume1111
DOIs
StatePublished - Sep 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1111
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Coccidioidomycosis
Transplants
Azoles
Transplantation
Infection
Immunosuppressive Agents
Mortality
Infection Control
Immunosuppression
Tissue Donors
Guidelines
Recurrence
Incidence
Therapeutics
Transplant Recipients

Keywords

  • Coccidioidomycosis
  • Fungal infections
  • Organ transplantation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Blair, J. E. (2007). Coccidioidomycosis in patients who have undergone transplantation. In Annals of the New York Academy of Sciences (Vol. 1111, pp. 365-376). (Annals of the New York Academy of Sciences; Vol. 1111). https://doi.org/10.1196/annals.1406.009

Coccidioidomycosis in patients who have undergone transplantation. / Blair, Janis E.

Annals of the New York Academy of Sciences. Vol. 1111 2007. p. 365-376 (Annals of the New York Academy of Sciences; Vol. 1111).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Blair, JE 2007, Coccidioidomycosis in patients who have undergone transplantation. in Annals of the New York Academy of Sciences. vol. 1111, Annals of the New York Academy of Sciences, vol. 1111, pp. 365-376. https://doi.org/10.1196/annals.1406.009
Blair JE. Coccidioidomycosis in patients who have undergone transplantation. In Annals of the New York Academy of Sciences. Vol. 1111. 2007. p. 365-376. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1406.009
Blair, Janis E. / Coccidioidomycosis in patients who have undergone transplantation. Annals of the New York Academy of Sciences. Vol. 1111 2007. pp. 365-376 (Annals of the New York Academy of Sciences).
@inproceedings{8da5c00f5f224642a86ed589ae126f5a,
title = "Coccidioidomycosis in patients who have undergone transplantation",
abstract = "In the early years of transplantation in Arizona, coccidioidomycosis occurred in 7{\%} to 9{\%} of recipients, with a mortality rate as high as 72{\%} in some cases. In current transplant programs, however, evolution of immunosuppression and institution of targeted prophylaxis have resulted in coccidioidal infection rates ranging from 1{\%} to 2{\%}. The clinical characteristics of this infection among transplant recipients range from asymptomatic to fulminant and fatal. Dissemination is common, and mortality is high (28{\%}). Because serologic response is often absent or slow, diagnosis can be challenging and often requires invasive diagnostic procedures. Pharmacologic treatment follows the guidelines of the Infectious Diseases Society of America, but control of infection may also dictate a decrease in immunosuppressant treatment. After infection is controlled, secondary azole prophylaxis is recommended to prevent relapse. Patients with a history of coccidioidomycosis may undergo successful transplantation when disease is inactive and azole prophylaxis is instituted. The incidence of donor-derived coccidioidomycosis is not known. The risk of coccidioidal infection among transplant recipients visiting in or relocating to an endemic area is low, and routine prophylaxis for this group is not recommended.",
keywords = "Coccidioidomycosis, Fungal infections, Organ transplantation",
author = "Blair, {Janis E.}",
year = "2007",
month = "9",
doi = "10.1196/annals.1406.009",
language = "English (US)",
isbn = "1573316881",
volume = "1111",
series = "Annals of the New York Academy of Sciences",
pages = "365--376",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Coccidioidomycosis in patients who have undergone transplantation

AU - Blair, Janis E.

PY - 2007/9

Y1 - 2007/9

N2 - In the early years of transplantation in Arizona, coccidioidomycosis occurred in 7% to 9% of recipients, with a mortality rate as high as 72% in some cases. In current transplant programs, however, evolution of immunosuppression and institution of targeted prophylaxis have resulted in coccidioidal infection rates ranging from 1% to 2%. The clinical characteristics of this infection among transplant recipients range from asymptomatic to fulminant and fatal. Dissemination is common, and mortality is high (28%). Because serologic response is often absent or slow, diagnosis can be challenging and often requires invasive diagnostic procedures. Pharmacologic treatment follows the guidelines of the Infectious Diseases Society of America, but control of infection may also dictate a decrease in immunosuppressant treatment. After infection is controlled, secondary azole prophylaxis is recommended to prevent relapse. Patients with a history of coccidioidomycosis may undergo successful transplantation when disease is inactive and azole prophylaxis is instituted. The incidence of donor-derived coccidioidomycosis is not known. The risk of coccidioidal infection among transplant recipients visiting in or relocating to an endemic area is low, and routine prophylaxis for this group is not recommended.

AB - In the early years of transplantation in Arizona, coccidioidomycosis occurred in 7% to 9% of recipients, with a mortality rate as high as 72% in some cases. In current transplant programs, however, evolution of immunosuppression and institution of targeted prophylaxis have resulted in coccidioidal infection rates ranging from 1% to 2%. The clinical characteristics of this infection among transplant recipients range from asymptomatic to fulminant and fatal. Dissemination is common, and mortality is high (28%). Because serologic response is often absent or slow, diagnosis can be challenging and often requires invasive diagnostic procedures. Pharmacologic treatment follows the guidelines of the Infectious Diseases Society of America, but control of infection may also dictate a decrease in immunosuppressant treatment. After infection is controlled, secondary azole prophylaxis is recommended to prevent relapse. Patients with a history of coccidioidomycosis may undergo successful transplantation when disease is inactive and azole prophylaxis is instituted. The incidence of donor-derived coccidioidomycosis is not known. The risk of coccidioidal infection among transplant recipients visiting in or relocating to an endemic area is low, and routine prophylaxis for this group is not recommended.

KW - Coccidioidomycosis

KW - Fungal infections

KW - Organ transplantation

UR - http://www.scopus.com/inward/record.url?scp=35348901947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348901947&partnerID=8YFLogxK

U2 - 10.1196/annals.1406.009

DO - 10.1196/annals.1406.009

M3 - Conference contribution

SN - 1573316881

SN - 9781573316880

VL - 1111

T3 - Annals of the New York Academy of Sciences

SP - 365

EP - 376

BT - Annals of the New York Academy of Sciences

ER -